New oral drug combo aims to wipe out lingering myeloma after transplant
NCT ID NCT05434689
Summary
This trial tests combination therapies with the oral drug iberdomide for patients with multiple myeloma who still have tiny amounts of cancer detectable after a stem cell transplant. The goal is to use these drug combinations to eliminate these remaining cancer cells and achieve a state called 'MRD-negative,' which is linked to better long-term control of the disease. The study will find safe doses and see how well the treatments work to clear the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27710, United States
-
Ohio State University Medical College
Columbus, Ohio, 43210, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
-
Vanderbilt University Medical College
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.